Open an account

Aldeyra Therapeutics

ALDX · NASDAQ

$0.7343+$0.0692 (+10.40%)TodayMarket closed ·
Prev close $0.6651

About ALDX

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

Employees
8
Headquarters
Lexington, Massachusetts
Listed
May 2, 2014
Sector
Health Care
Industry
Biotechnology
Website
aldeyra.com

ALDX key statistics

Market cap
40.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.02M
Volume
1.56M
Open price
$0.654
High today
$0.7484
Low today
$0.6501
52 Week high
$5.93
52 Week low
$0.6501

Aldeyra Therapeutics (ALDX) at a glance

Aldeyra Therapeutics (ALDX) last traded at $0.7343, with a market cap of 40.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6501 and $0.7484. The current price is 13.0% above the day's low and 1.9% below its high.

Volume so far is 1.56M shares, below the average of 2.02M shares a day.

Over the past year Aldeyra Therapeutics has ranged from $0.6501 to $5.93, and now sits 2% of the way up that range.

Aldeyra Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.09 per share against an estimate of -$0.0959.

The average analyst price target is $7.31, 895.5% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 8 analystsAvg $7.31
Low
$2.02
Now
$0.7343
High
$13.65

ALDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 34.9% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.1446
  2. Q4 FY24: reported -$0.27 per share against an estimate of -$0.2519
  3. Q1 FY25: reported -$0.17 per share against an estimate of -$0.2298
  4. Q2 FY25: reported -$0.13 per share against an estimate of -$0.2499
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.2499
  6. Q4 FY25: reported -$0.10 per share against an estimate of -$0.1714
  7. Q1 FY26: reported -$0.06 per share against an estimate of -$0.0995
  8. Q2 FY26: reported -$0.09 per share against an estimate of -$0.0959

ALDX news

  • Vandana Singh

    Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally

  • Press releaseBusiness Wire

    Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

  • Press releaseBusiness Wire

    Aldeyra Therapeutics to Host Regulatory Update Webcast

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseBusiness Wire

    Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

  • Press releaseBusiness Wire

    Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

  • Press releaseBusiness Wire

    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • Press releaseBusiness Wire

    ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

Similar companies

Companies in the same industry as Aldeyra Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.